Omeros Corporation (Nasdaq: OMER) today announced the publication of a peer-reviewed manuscript in Blood Advances, a journal ...

A research team has outlined how synthetic biology can accelerate discoveries in plant–microbe interactions, offering ...

Claseprubart is an investigational, clinical-stage, potent monoclonal antibody engineered to selectively target the classical pathway by inhibiting only the active form of the C1s protein, a ...

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced the publication of a peer-reviewed manuscript in the American Journal of Hematology detailing survival outcomes in adult and ...

Omeros Corporation (Nasdaq: OMER) today announced the publication of a peer-reviewed manuscript in the American Journal of Hematology detailing survival outcomes in adult and pediatric patients with ...

BYU-Pathway Worldwide students in Lagos, Nigeria gather in March 2024. Enrollment in Nigeria surged from 6,603 students in 2023 to 11,724 in 2024. With higher education experiencing unprecedented ...

MBL (mannose-binding lectin), a pattern recognition molecule circulating in complex with MASPs (MBL-associated serine proteases), activates the lectin complement pathway and facilitates thrombin ...

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the Biologics License ...

C3G and IC-MPGN both cause protein deposits that reduce kidney function. Overactive proteins in the immune system lead to these different conditions. C3G and IC-MPGN are rare kidney conditions. They ...

Good morning and good afternoon, everyone. Thank you for joining us today. My name is Gem Hopkins, Vice President of Investor Relations and Corporate Communications at Silence. Joining me on today’s ...